Literature DB >> 8231802

The interaction between coumarin drugs and DNA gyrase.

A Maxwell1.   

Abstract

The coumarin group of antibiotics have as their target the bacterial enzyme DNA gyrase. The drugs bind to the B subunit of gyrase and inhibit DNA supercoiling by blocking the ATPase activity. Recent data show that the binding site for the drugs lies within the N-terminal part of the B protein, and individual amino acids involved in coumarin interaction are being identified. The mode of inhibition of the gyrase ATPase reaction by coumarins is unlikely to be simple competitive inhibition, and the drugs may act by stabilizing a conformation of the enzyme with low affinity for ATP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8231802     DOI: 10.1111/j.1365-2958.1993.tb01728.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  54 in total

1.  Transcriptional coupling between the divergent promoters of a prototypic LysR-type regulatory system, the ilvYC operon of Escherichia coli.

Authors:  K Y Rhee; M Opel; E Ito; S p Hung; S M Arfin; G W Hatfield
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

2.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.

Authors:  Christine D Hardy; Nicholas R Cozzarelli
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

4.  DNA gyrase can cleave short DNA fragments in the presence of quinolone drugs.

Authors:  M E Cove; A P Tingey; A Maxwell
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

5.  Modulation of S. aureus and P. aeruginosa biofilm: an in vitro study with new coumarin derivatives.

Authors:  Tapas Das; Manash C Das; Antu Das; Sukhen Bhowmik; Padmani Sandhu; Yusuf Akhter; Surajit Bhattacharjee; Utpal Ch De
Journal:  World J Microbiol Biotechnol       Date:  2018-11-08       Impact factor: 3.312

6.  Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase.

Authors:  M Oram; B Dosanjh; N A Gormley; C V Smith; L M Fisher; A Maxwell; K Duncan
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.

Authors:  Katherine A Hurley; Thiago M A Santos; Molly R Fensterwald; Madhusudan Rajendran; Jared T Moore; Edward I Balmond; Brice J Blahnik; Katherine C Faulkner; Marie H Foss; Victoria A Heinrich; Matthew G Lammers; Lucas C Moore; Gregory D Reynolds; Galen P Shearn-Nance; Brian A Stearns; Zi W Yao; Jared T Shaw; Douglas B Weibel
Journal:  Medchemcomm       Date:  2017-02-27       Impact factor: 3.597

8.  gyrB mutations in coumermycin A1-resistant Borrelia burgdorferi.

Authors:  D S Samuels; R T Marconi; W M Huang; C F Garon
Journal:  J Bacteriol       Date:  1994-05       Impact factor: 3.490

9.  RNA polymerase (rpoB) mutants selected for increased resistance to gyrase inhibitors in Salmonella typhimurium.

Authors:  A B Blanc-Potard; E Gari; F Spirito; N Figueroa-Bossi; L Bossi
Journal:  Mol Gen Genet       Date:  1995-06-25

10.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.